MEOBF (MEOBF) Stock Price & Analysis
MEOBF (MEOBF) rose 0.00% to USD 1.7 as of June 10, 2026 at 06:04 UTC, according to Nexqual real-time market data.
MEOBF last closed at USD 1.7; the session ranged USD 1.7–1.7 on volume of 5,000 shares. Market capitalization is $2.20B, with a 52-week range of USD 0.96–2.59 (PNK). Source: Nexqual, June 10, 2026 at 06:04 UTC.
Key Statistics (as of June 10, 2026 at 06:04 UTC)
| Price | USD 1.7 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 1.7 |
| Open | USD 1.7 |
| Day Range | USD 1.7 – 1.7 |
| 52-Week Range | USD 0.96 – 2.59 |
| Volume | 5,000 shares |
| Market Cap | $2.20B |
| Exchange | PNK |
Technical Analysis (MEOBF)
Nexqual's technical model rates MEOBF "SELL" based on 3 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 06:04 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 0 (oversold) |
| vs SMA50 | Above (USD 1.67) |
| MACD | -0 (negative) |
Analyst Ratings (MEOBF)
Wall Street analysts rate MEOBF "None", per Nexqual as of June 10, 2026 at 06:04 UTC.
| Consensus Rating | None |
|---|
Earnings (MEOBF)
| Revenue Estimate | $47.13M |
|---|
Source: Nexqual, June 10, 2026 at 06:04 UTC.
Financials & Fundamentals (MEOBF)
| Total Revenue | $65.38M |
|---|---|
| Revenue Growth (YoY) | +1526.80% |
| Gross Margin | -35.53% |
| Operating Margin | -55.16% |
| Profit Margin | -144.33% |
| ROE | -18.22% |
| Debt / Equity | 23.52 |
| Current Ratio | 1.58 |
| Total Cash | $129.97M |
| Total Debt | $135.14M |
| Free Cash Flow | $-69.44M |
Source: Nexqual, June 10, 2026 at 06:04 UTC.
Financial Health Score (MEOBF)
Nexqual rates MEOBF's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 06:04 UTC.
| Growth | Strong — Revenue +203% YoY (annual) |
|---|---|
| Profitability | Weak — Not yet profitable — scaling phase |
| Balance Sheet | Strong — $130M cash vs $135M debt |
| Cash Flow | Weak — FCF negative: -$69M, burning cash |
| Efficiency | Critical — ROE -18%, ROA -6.2% |
Ownership (MEOBF)
| Insider Ownership | +36.25% |
|---|---|
| Institutional Ownership | +16.56% |
| Shares Outstanding | 1.29B |
| Float | 833.84M |
Source: Nexqual, June 10, 2026 at 06:04 UTC.
Leadership (MEOBF)
MEOBF is led by Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons) (age 68), Founder, CEO, MD, Chairman of Scientific Advisory Board & Executive Director, per Nexqual as of June 10, 2026 at 06:04 UTC.
| Founder, CEO, MD, Chairman of Scientific Advisory Board & Executive Director | Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons) (age 68) |
|---|---|
| Chief Medical Officer & Executive Director | Eric A. Rose (age 74) |
| Chief Financial Officer | James Michael O'Brien (age 59) |
Major Backers & Investors (MEOBF)
Notable institutional backers of MEOBF include DFA INVESTMENT TRUST CO-The Asia Pacific Small Company Series, Charles Schwab, according to Nexqual as of June 10, 2026 at 06:04 UTC.
Active Investors
| Investor | Stake |
|---|---|
| DFA INVESTMENT TRUST CO-The Asia Pacific Small Company Series | 0.42% |
| Charles Schwab | 0.15% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 1.97% |
| BlackRock | 0.81% |
Source: Nexqual, June 10, 2026 at 06:04 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MESO | Mesoblast Limited | USD 14.28 | ▲ 2.37% |
| PTCHF | PureTech Health PLC | USD 1.8 | ▼ 3.33% |
| PHGUF | Pharming Group NV | USD 1.18 | ▲ 0% |
| PTKFF | KALBE FARMA | USD 0.04 | ▲ 0% |
| OXBDF | Oxford Biomedica PLC | USD 8.44 | ▲ 6.63% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 06:04 UTC. This page is informational and not investment advice.